Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announc

BOSTON, MA / ACCESSWIRE / May 21, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

Related Keywords

Washington , District Of Columbia , United States , Ukraine , Boston , Massachusetts , American , Joe Patneaude , Gewinn Nur , Pieris Pharmaceuticals , American Thoracic Society , Pieris Pharmaceuticals Inc , Company Quarterly Reports On Form , Nasdaq , Pieris Pharmaceuticals Inc View , International Conference , Securities Exchange , Exchange Commission , Chief Development Officer , Securities Act , Securities Exchange Act , Annual Report , Quarterly Reports , Relations Contact , Inc View , Pieris , Pharmaceuticals , Nnounces , Presentation , Romising , Reclinical , Data , 023 , Nternational , Conference ,